As the leader of the On The Pen community, I am deeply concerned about the potential impact of the SAFE Drugs Act on the nearly 200,000 individuals I represent. Many in our community rely on compounded GLP-1 treatments, which have proven to be vital in managing their health conditions while minimizing side effects and navigating a system never designed to address a problem this large. I am painfully aware that many in my community face barriers such as denials, insurance exclusions, and unbearable side effects. These challenges make it difficult, if not impossible, for patients to access the treatments they need to maintain their health and avoid more serious health complications. Worse yet, any major disruption to compounded meds would mean that tens of thousands could face dangerous interruptions to care.

The proposed SAFE Drugs Act threatens to further limit access to compounded medications, which are often the only viable option for individuals who cannot afford brandname pharmaceuticals or who need customized treatment approaches. For many facing chronic health issues, compounded GLP-1 medications are not just an option but a necessity. The potential restrictions could result in dire health outcomes, as patients might be forced to halt their treatments altogether due to prohibitive costs or the absence of an appropriate alternative.

There is ample evidence demonstrating the efficacy and safety of compounded GLP-1 treatments. Yet, the SAFE Drugs Act, under the guise of safety regulation, risks cutting off critical supply lines that provide patients with life-saving alternatives. According to recent studies, these treatments have significantly improved the quality of life for those with diabetes and other related health conditions, helping them to better control blood sugar levels and prevent serious complications.

We urge lawmakers to consider the real-life impacts of the SAFE Drugs Act. The potential benefits of safeguarding access to lifesaving treatments far outweigh the perceived regulatory gains of the Act. It is crucial that any legislation take into consideration the voices of those who will be most affected, millions of patients who depend on compounded medications for their health and well-being.

We call on policymakers to protect patient access to essential compounded GLP-1 treatments by rejecting or amending the SAFE Drugs Act to ensure that it does not inadvertently harm those it aims to protect. Please sign this petition and help us stand up for patients' rights to access affordable and necessary healthcare options.